Another Disappointing Year for Drug Approvals

New molecular entity approvals dipped in 2010 and Innovative Commercial Therapies dropped even more sharply. Add to that a significant drop in filings in 2010 and it is hard to be optimistic about a turnaround in approval numbers any time soon.